Key facts
- This page summarizes Maria-Luisa Maccecchini's Form 4 filing for Lantern Pharma Inc. (LTRN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2026, 16:05.
Maria-Luisa Maccecchini - 09 Jan 2026 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)
- Reporting relationship
- Director
- Issuer ticker
- LTRN
- Reported as of
- 09 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2026, 16:05:12 UTC
- Prior SEC filing
- 12 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Maria Luisa Maccecchini
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Maria-Luisa Maccecchini filed Form 4 for Lantern Pharma Inc. (LTRN) on 13 Jan 2026.
Change
- Previous filing in this sequence was filed on 12 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001315018
Primary reporting owner
Maccecchini Maria-Luisa
- Relationship
- Director
- Address
- 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS
- Signature
- /s/ Maria Luisa Maccecchini
- Signature date
- 12 Jan 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LTRN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 09 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $3.49
- Footnotes
- F1
LTRN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +21,152
- Change %
- Price
- $0.000000
- Shares after
- 21,152
- Date
- 09 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,152
- Exercise price
- $3.49
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.
Footnote F2
The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.